An Open-label, Randomized, Active-Controlled, Phase 3 Study of Setrusumab Compared With Bisphosphonates in Pediatric Subjects 2 to < 5 Years of Age With Osteogenesis Imperfecta Types I, III or IV
![](https://researchstudies.cuanschutz.edu/Content/images/study-category-images/genetics.jpg)
Details
Age
Child
Eligibility
Diagnosis of Osteogenesis Imperfecta with more than 1 fracture in the past 12 months, 2 fractures in past 24 months, or 1 femur, tibia, or humerus fracture in last 24 months AND between ages 2 to <5
Locations
Childrens Hospital Colorado
Principal Investigator
![Photograph of Klane White](https://som.ucdenver.edu/FIMS/Content/faculty/37615/CU-Doctors-37615.jpg)
Klane White
Study ID
Protocol Number: 23-0369
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers